Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces it has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I clinical trial of TG6050, a novel oncolytic virus (OV) that will be administered intravenously in patients with advanced non-small cell lung cancer (NSCLC).
TG6050 has been generated using Transgene
